Haleon Shares Drop Over 2% in Premarket Trading as Q1 Organic Sales Growth Misses Expectations

Gelonghui April 29 | Haleon (HLN.US) fell 2.32% pre-market, trading at $9.25. Due to weak demand for over-the-counter cold and flu medications at the beginning of the year, Haleon's Q1 results were below expectations. The company’s organic sales growth in Q1 was 2.2%, lower than the analysts' expected 2.4%. Haleon had warned that the weak cold and flu season at the end of 2025 would extend into the new fiscal year. (Gelonghui)